

Nevro Corp (NVRO) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/NCF0DA56C90EN.html

Date: April 2021 Pages: 47 Price: US\$ 125.00 (Single User License) ID: NCF0DA56C90EN

Abstracts

Nevro Corp (NVRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nevro Corp (Nevro) is a medical device company which focuses on providing novel products that advance the quality of life of people suffering from chronic pain in trunks and limbs. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Nevro Senza SCS system is commercially available in the US, Europe and Australia. The company offers products under Senza, Senza II, Senza Omnia and the Nevro logo brands. Nevro is developing HF10 therapy for treating painful diabetic neuropathy and non-surgical refractory back pain. Nevro is headquartered in Redwood City, California, the US.

Nevro Corp Key Recent Developments

Apr 13,2021: Nevro to Present at BofA Securities 2021 Virtual Health Care Conference Feb 24,2021: Nevro reports fourth quarter and full year 2020 financial results Jan 11,2021: Nevro announces preliminary, unaudited fourth quarter and full-year 2020 revenue

Dec 14,2020: Boston Scientific announces stipulation of dismissal of Nevro Corporation's patent infringement case in California Dec 03,2020: Nevro announces director appointment



Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.



Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Nevro Corp - Key Facts Nevro Corp - Key Employees Nevro Corp - Key Employee Biographies Nevro Corp - Major Products and Services Nevro Corp - History Nevro Corp - History Nevro Corp - Company Statement Nevro Corp - Locations And Subsidiaries Head Office Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

- Nevro Corp Business Description
- Geographical Segment: International
- Target Markets
- Performance
- Geographical Segment: The US
- Performance
- **R&D** Overview
- Nevro Corp Corporate Strategy
- Nevro Corp SWOT Analysis
- SWOT Analysis Overview
- Nevro Corp Strengths
- Nevro Corp Weaknesses
- Nevro Corp Opportunities
- Nevro Corp Threats
- Nevro Corp Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance



Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Nevro Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021 Nevro Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021 Nevro Corp, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Apr 13, 2021: Nevro to Present at BofA Securities 2021 Virtual Health Care Conference Feb 24, 2021: Nevro reports fourth quarter and full year 2020 financial results Jan 11, 2021: Nevro announces preliminary, unaudited fourth quarter and full-year 2020 revenue Dec 14, 2020: Boston Scientific announces stipulation of dismissal of Nevro Corporation's patent infringement case in California Dec 03, 2020: Nevro announces director appointment Nov 30, 2020: Nevro announces director appointment Nov 30, 2020: Nevro appoints Julie D. Dewey as vice president, investor relations and corporate communications Nov 05, 2020: Nevro announces third quarter 2020 financial results Sep 14, 2020: Nevro initiates plan for manufacturing operations in Costa Rica to support future growth Aug 05, 2020: Nevro announces second quarter 2020 financial results Jun 04, 2020: Nevro appoints finance executive Roderick MacLeod as Chief Financial

Officer

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

- Nevro Corp, Key Facts
- Nevro Corp, Key Employees
- Nevro Corp, Key Employee Biographies
- Nevro Corp, Major Products and Services
- Nevro Corp, History
- Nevro Corp, Subsidiaries
- Nevro Corp, Key Competitors
- Nevro Corp, Ratios based on current share price
- Nevro Corp, Annual Ratios
- Nevro Corp, Annual Ratios (Cont...1)
- Nevro Corp, Interim Ratios
- Nevro Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
- Nevro Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
- Nevro Corp, Recent Deals Summary
- **Currency Codes**
- Capital Market Ratios
- **Equity Ratios**
- **Profitability Ratios**
- **Cost Ratios**
- Liquidity Ratios
- Leverage Ratios
- **Efficiency Ratios**



List Of Figures

LIST OF FIGURES

Nevro Corp, Performance Chart (2016 - 2020) Nevro Corp, Ratio Charts Nevro Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021 Nevro Corp, Medical Equipment, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Nevro Corp (NVRO) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/NCF0DA56C90EN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/NCF0DA56C90EN.html</u>